BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenberg A, Mahalingam D. Immunotherapy in pancreatic adenocarcinoma-overcoming barriers to response. J Gastrointest Oncol. 2018;9:143-159. [PMID: 29564181 DOI: 10.21037/jgo.2018.01.13] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Liu X, Jiang J, Liao YP, Tang I, Zheng E, Qiu W, Lin M, Wang X, Ji Y, Mei KC, Liu Q, Chang CH, Wainberg ZA, Nel AE, Meng H. Combination Chemo-Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti-PD-1. Adv Sci (Weinh) 2021;8:2002147. [PMID: 33747719 DOI: 10.1002/advs.202002147] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
2 Solanki A, King D, Thibault G, Wang L, Gibbs SL. Quantification of fluorophore distribution and therapeutic response in matched in vivo and ex vivo pancreatic cancer model systems. PLoS One 2020;15:e0229407. [PMID: 32097436 DOI: 10.1371/journal.pone.0229407] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Bahmani B, Uehara M, Ordikhani F, Li X, Jiang L, Banouni N, Ichimura T, Kasinath V, Eskandari SK, Annabi N, Bromberg JS, Shultz LD, Greiner DL, Abdi R. Ectopic high endothelial venules in pancreatic ductal adenocarcinoma: A unique site for targeted delivery. EBioMedicine 2018;38:79-88. [PMID: 30497977 DOI: 10.1016/j.ebiom.2018.11.030] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
4 Guo S, Burcus NI, Hornef J, Jing Y, Jiang C, Heller R, Beebe SJ. Nano-Pulse Stimulation for the Treatment of Pancreatic Cancer and the Changes in Immune Profile. Cancers (Basel) 2018;10:E217. [PMID: 29954062 DOI: 10.3390/cancers10070217] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
5 Ghidini M, Lampis A, Mirchev MB, Okuducu AF, Ratti M, Valeri N, Hahne JC. Immune-Based Therapies and the Role of Microsatellite Instability in Pancreatic Cancer. Genes (Basel) 2020;12:33. [PMID: 33383713 DOI: 10.3390/genes12010033] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Li T, Zhao H, Zhou H, Geng T. LncRNA LINC00857 strengthens the malignancy behaviors of pancreatic adenocarcinoma cells by serving as a competing endogenous RNA for miR-340-5p to upregulate TGFA expression. PLoS One 2021;16:e0247817. [PMID: 33661995 DOI: 10.1371/journal.pone.0247817] [Reference Citation Analysis]
7 Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson WE 3rd, Mace TA. CD200 promotes immunosuppression in the pancreatic tumor microenvironment. J Immunother Cancer 2020;8:e000189. [PMID: 32581043 DOI: 10.1136/jitc-2019-000189] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mahmood J, Alexander AA, Samanta S, Kamlapurkar S, Singh P, Saeed A, Carrier F, Cao X, Shukla HD, Vujaskovic Z. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice. Cancers (Basel) 2020;12:E1015. [PMID: 32326142 DOI: 10.3390/cancers12041015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kole C, Charalampakis N, Tsakatikas S, Frountzas M, Apostolou K, Schizas D. Immunotherapy in Combination with Well-Established Treatment Strategies in Pancreatic Cancer: Current Insights. CMAR 2022;Volume 14:1043-61. [DOI: 10.2147/cmar.s267260] [Reference Citation Analysis]
10 Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who received definitive surgery of the pancreatic tumor: a retrospective analysis of the National Cancer Database. Radiat Oncol 2020;15:139. [PMID: 32493354 DOI: 10.1186/s13014-020-01569-5] [Reference Citation Analysis]
11 Wang W, Xing H, Huang C, Pan H, Li D. Identification of pancreatic cancer type related factors by Weighted Gene Co-Expression Network Analysis. Med Oncol 2020;37:33. [PMID: 32200436 DOI: 10.1007/s12032-020-1339-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
12 Mahalingam D, Goel S, Aparo S, Patel Arora S, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Gutierrez A, Coffey M, Nawrocki ST, Nuovo G, Mita MM. A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E160. [PMID: 29799479 DOI: 10.3390/cancers10060160] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 12.5] [Reference Citation Analysis]
13 Preston CC, Faustino RS. Nuclear Envelope Regulation of Oncogenic Processes: Roles in Pancreatic Cancer. Epigenomes 2018;2:15. [PMID: 31867128 DOI: 10.3390/epigenomes2030015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Amin S, Baine M, Meza J, Alam M, Lin C. The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. Clin Transl Radiat Oncol 2020;24:34-40. [PMID: 32613090 DOI: 10.1016/j.ctro.2020.06.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
15 Schizas D, Charalampakis N, Kole C, Economopoulou P, Koustas E, Gkotsis E, Ziogas D, Psyrri A, Karamouzis MV. Immunotherapy for pancreatic cancer: A 2020 update.Cancer Treat Rev. 2020;86:102016. [PMID: 32247999 DOI: 10.1016/j.ctrv.2020.102016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 15.5] [Reference Citation Analysis]
16 Kaur J, Mir T, Gill R, Duong J, Marcus S, Khan R. Immunotherapeutic approach for advanced pancreatic adenocarcinoma. Immunotherapy 2021;13:767-82. [PMID: 33910383 DOI: 10.2217/imt-2020-0344] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Pretta A, Lai E, Persano M, Donisi C, Pinna G, Cimbro E, Parrino A, Spanu D, Mariani S, Liscia N, Dubois M, Migliari M, Impera V, Saba G, Pusceddu V, Puzzoni M, Ziranu P, Scartozzi M. Uncovering key targets of success for immunotherapy in pancreatic cancer. Expert Opin Ther Targets 2021;:1-19. [PMID: 34806517 DOI: 10.1080/14728222.2021.2010044] [Reference Citation Analysis]
18 Ding J, Lu X. Expression of miR-204 in pediatric retinoblastoma and its effects on proliferation and apoptosis of cancer cells. Oncol Lett 2018;16:7152-7. [PMID: 30546451 DOI: 10.3892/ol.2018.9519] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
19 Liu Y, Liu Z, Zeng X, Bai C, Chen L, Lin S, Tian X. Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma. BMC Cancer 2019;19:1193. [PMID: 31805889 DOI: 10.1186/s12885-019-6372-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
20 Amin S, Baine M, Meza J, Lin C. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis. BMC Cancer 2020;20:538. [PMID: 32517661 DOI: 10.1186/s12885-020-07016-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
21 Van Loenhout J, Flieswasser T, Freire Boullosa L, De Waele J, Van Audenaerde J, Marcq E, Jacobs J, Lin A, Lion E, Dewitte H, Peeters M, Dewilde S, Lardon F, Bogaerts A, Deben C, Smits E. Cold Atmospheric Plasma-Treated PBS Eliminates Immunosuppressive Pancreatic Stellate Cells and Induces Immunogenic Cell Death of Pancreatic Cancer Cells. Cancers (Basel) 2019;11:E1597. [PMID: 31635070 DOI: 10.3390/cancers11101597] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
22 MacNeil T, Vathiotis IA, Shafi S, Aung TN, Zugazagoitia J, Gruver AM, Driscoll K, Rimm DL. Multiplex Quantitative Analysis of Tumor-Infiltrating Lymphocytes, Cancer-Associated Fibroblasts, and CD200 in Pancreatic Cancer. Cancers (Basel) 2021;13:5501. [PMID: 34771664 DOI: 10.3390/cancers13215501] [Reference Citation Analysis]
23 Cherri S, Noventa S, Zaniboni A. Pancreatic adenocarcinoma: Beyond first line, where are we? World J Gastroenterol 2021; 27(17): 1847-1863 [PMID: 34007126 DOI: 10.3748/wjg.v27.i17.1847] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
24 Liu X, Sun H, Wang X, Meng H. Immunological effects of nano-enabled hyperthermia for solid tumors: opportunity and challenge. Front Chem Sci Eng 2022;16:333-44. [DOI: 10.1007/s11705-021-2059-5] [Reference Citation Analysis]
25 Tran TB, Maker VK, Maker AV. Impact of Immunotherapy after Resection of Pancreatic Cancer. J Am Coll Surg 2019;229:19-27.e1. [PMID: 30742911 DOI: 10.1016/j.jamcollsurg.2019.01.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
26 Wang ZC, Huang FZ, Xu HB, Sun JC, Wang CF. MicroRNA-137 inhibits autophagy and chemosensitizes pancreatic cancer cells by targeting ATG5. Int J Biochem Cell Biol. 2019;111:63-71. [PMID: 30710750 DOI: 10.1016/j.biocel.2019.01.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
27 Willumsen N, Ali SM, Leitzel K, Drabick JJ, Yee N, Polimera HV, Nagabhairu V, Krecko L, Ali A, Maddukuri A, Moku P, Ali A, Poulose J, Menon H, Pancholy N, Costa L, Karsdal MA, Lipton A. Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer. Sci Rep 2019;9:19761. [PMID: 31875000 DOI: 10.1038/s41598-019-56268-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
28 Trunk A, Miotke L, Nevala-Plagemann C, Verdaguer H, Macarulla T, Garrido-Laguna I. Emerging Treatment Strategies in Pancreatic Cancer. Pancreas 2021;50:773-87. [PMID: 34398070 DOI: 10.1097/MPA.0000000000001845] [Reference Citation Analysis]